These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38134458)

  • 1. Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers.
    Lashen A; Al-Kawaz A; Jeyapalan JN; Alqahtani S; Shoqafi A; Algethami M; Toss M; Green AR; Mongan NP; Sharma S; Akbari MR; Rakha EA; Madhusudan S
    Neoplasia; 2024 Jan; 47():100957. PubMed ID: 38134458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
    Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
    Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
    Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
    Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RECQL: a new breast cancer susceptibility gene.
    Banerjee T; Brosh RM
    Cell Cycle; 2015; 14(22):3540-3. PubMed ID: 26125302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of germline mutations in breast cancer genes: RECQL.
    Bowden AR; Tischkowitz M
    Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
    Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
    BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
    Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
    Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer.
    Sun J; Wang Y; Xia Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Lou H; Xie Y
    PLoS Genet; 2015 May; 11(5):e1005228. PubMed ID: 25945795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
    Kim M; Choi HY; Woo JW; Chung YR; Park SY
    Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    Xu H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2018 Jun; 18(1):662. PubMed ID: 29914420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
    Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
    Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline RECQL mutations in high risk Chinese breast cancer patients.
    Kwong A; Shin VY; Cheuk IWY; Chen J; Au CH; Ho DN; Chan TL; Ma ESK; Akbari MR; Narod SA
    Breast Cancer Res Treat; 2016 Jun; 157(2):211-215. PubMed ID: 27125668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
    Allred DC; Wu Y; Mao S; Nagtegaal ID; Lee S; Perou CM; Mohsin SK; O'Connell P; Tsimelzon A; Medina D
    Clin Cancer Res; 2008 Jan; 14(2):370-8. PubMed ID: 18223211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
    Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
    Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
    J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.